See All News - tctmd.com

News

News Industry News

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

January 04, 2011

News Daily News

Benefit of Sirolimus Stents Sharply Attenuated in Dialysis Patients

January 04, 2011

News Daily News

Final Kissing Balloon Unnecessary in Single-Stent Approach to Bifurcation Lesions

Caitlin E. Cox

January 04, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

January 04, 2011

News Industry News

OrbusNeich Granted Expanded U.S. Patent of GenousTM Endothelial Progenitor Cell Capture Technology

January 03, 2011

News Daily News

PLATO CABG Cohort: Ticagrelor Cuts Total and CV Mortality in Half

L.A. McKeown

January 03, 2011

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2010

Jason Kahn

January 02, 2011

News Industry News

Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia

January 02, 2011

News Daily News

Year in Review: Highlights of 2010 Include Data on Valvular Therapy, CTA Progress

Caitlin E. Cox

January 02, 2011

News

PARTNER: All-Cause, CV Mortality Lower in Patients Treated with TAVI vs. Standard Therapy at 1 Year

TCT Daily Staff

September 23, 2010

Advertisement

News

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

Benefit of Sirolimus Stents Sharply Attenuated in Dialysis Patients

Final Kissing Balloon Unnecessary in Single-Stent Approach to Bifurcation Lesions

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

OrbusNeich Granted Expanded U.S. Patent of GenousTM Endothelial Progenitor Cell Capture Technology

PLATO CABG Cohort: Ticagrelor Cuts Total and CV Mortality in Half

TCTMD’s Top 10 Most Popular News Stories for 2010

Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia

Year in Review: Highlights of 2010 Include Data on Valvular Therapy, CTA Progress

PARTNER: All-Cause, CV Mortality Lower in Patients Treated with TAVI vs. Standard Therapy at 1 Year

Search News

Advertisement

Advertisement

News

Search News

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content